Novavax Inc. [NVAX] stock Initiated by BofA Securities analyst, price target now $35

Novavax Inc. [NASDAQ: NVAX] traded at a high on 08/24/22, posting a 1.42 gain after which it closed the day’ session at $37.07. The company report on August 21, 2022 that U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Adolescents Aged 12 Through 17.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Novavax’ vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.

Doses of the Novavax COVID-19 Vaccine, Adjuvanted are now available and primary series immunizations for adolescents can begin once a policy recommendation from the CDC is received.

The results of the trading session contributed to over 2730934 shares changing hands. Over the past one week, the price volatility of Novavax Inc. stands at 6.01% while the volatility over the past one month is 7.70%.

The market cap for NVAX stock reached $2.98 billion, with 78.14 million shares outstanding and 77.85 million shares in the current float. Compared to the average trading volume of 7.58M shares, NVAX reached a trading volume of 2730934 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Novavax Inc. [NVAX]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVAX shares is $124.60 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVAX stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

BofA Securities have made an estimate for Novavax Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on May 20, 2022. While these analysts kept the previous recommendation, B. Riley Securities dropped their target price from $315 to $265. The new note on the price target was released on February 23, 2022, representing the official price target for Novavax Inc. stock. Previously, the target price had yet another raise to $198, while Jefferies analysts kept a Buy rating on NVAX stock.

The Average True Range (ATR) for Novavax Inc. is set at 4.03, with the Price to Sales ratio for NVAX stock in the period of the last 12 months amounting to 2.31.

How has NVAX stock performed recently?

Novavax Inc. [NVAX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.84. With this latest performance, NVAX shares dropped by -34.45% in over the last four-week period, additionally sinking by -53.31% over the last 6 months – not to mention a drop of -85.23% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVAX stock in for the last two-week period is set at 34.91, with the RSI for the last a single of trading hit 30.84, and the three-weeks RSI is set at 38.57 for Novavax Inc. [NVAX]. The present Moving Average for the last 50 days of trading for this stock 51.79, while it was recorded at 36.50 for the last single week of trading, and 88.40 for the last 200 days.

Novavax Inc. [NVAX]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Novavax Inc. [NVAX] shares currently have an operating margin of -147.13 and a Gross Margin at +98.90. Novavax Inc.’s Net Margin is presently recorded at -152.12.

Return on Equity for this stock declined to -1,265.72, with Return on Assets sitting at -83.85.

Novavax Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.90 and a Current Ratio set at 1.00.

Earnings analysis for Novavax Inc. [NVAX]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVAX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Novavax Inc. go to 0.00%.

Insider trade positions for Novavax Inc. [NVAX]

There are presently around $1,257 million, or 44.80% of NVAX stock, in the hands of institutional investors. The top three institutional holders of NVAX stocks are: VANGUARD GROUP INC with ownership of 7,350,925, which is approximately 5.511% of the company’s market cap and around 0.20% of the total institutional ownership; BLACKROCK INC., holding 4,258,441 shares of the stock with an approximate value of $157.86 million in NVAX stocks shares; and STATE STREET CORP, currently with $109.98 million in NVAX stock with ownership of nearly 18.887% of the company’s market capitalization.

158 institutional holders increased their position in Novavax Inc. [NASDAQ:NVAX] by around 6,888,394 shares. Additionally, 216 investors decreased positions by around 6,553,836 shares, while 66 investors held positions by with 20,472,387 shares. The mentioned changes placed institutional holdings at 33,914,617 shares, according to the latest SEC report filing. NVAX stock had 59 new institutional investments in for a total of 1,247,440 shares, while 111 institutional investors sold positions of 2,488,574 shares during the same period.


Please enter your comment!
Please enter your name here